RE-GEND, NCT02761070: Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III |
|
|
| Active, not recruiting | 3 | 146 | Japan | Temozolomide, Temodar, Temodal, Bevacizumab, Avastin | Kyorin University, Japan Clinical Oncology Group | Glioblastoma, Recurrence, Progression | 11/25 | 11/25 | | |